• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Acorda’s inhaled Parkinson’s drug meets primary endpoint in Phase III trial

February 9, 2017 By Sarah Faulkner

Acorda TherapeuticsAcorda's inhaled Parkinson's drug meets primary endpoint in Phase III trial (NSDQ:ACOR) said today that the phase III clinical trial evaluating its inhaled formulation of Parkinson’s drug levodopa met its primary endpoint. The drug was studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms.

The randomized phase III trial enrolled 339 patients to evaluate the efficacy and safety of CVT-301 compared with a placebo in patients with Parkinson’s who experience motor fluctuations. Study participants self-administered the therapy up to 5 times per day for 12 weeks.

The study’s primary endpoint was a change in the Unified Parkinson’s Disease Rating Scale score at week 12 relative to a placebo at 30 minutes post-treatment. Secondary endpoints included the proportion of participants who achieved an “on” state within 60 minutes of treatment and maintained at 60 minutes, as well as total daily “off” time as recorded in participants’ logs.

The trial participants were randomized into 3 arms – a group that received an 84 mg dose, a 60 mg dose and a placebo. The UPDRS change for the 84 mg dose was -9.83 compared to -5.91 for their counterparts in the control group.

The inhaled drug’s safety profile was consistent with results observed in the phase IIb trial. The company said it is conducting 2 studies to assess the long-term safety profile of CVT-301, which it will present at the end of the 1st quarter this year.

“We are greatly encouraged by the efficacy and safety results of this trial, which validate the positive Phase IIb results,” chief medical officer Dr. Burkhard Blank said in prepared remarks. “We would like to express our gratitude to the study volunteers and clinical investigators who participated in this trial to advance our understanding of this potentially important therapy for people with Parkinson’s.”

Acorda said it plans to file a New Drug Application in the U.S. by the end of the 2nd quarter this year, contingent on the company’s long-term safety studies. The company also said it anticipates it will file a Marketing Authorization Application in Europe by the end of this year.

“The re-emergence of Parkinson’s disease symptoms has a major negative impact on the lives of people with this disease, as well as on their families and care partners,” lead investigator Dr. Peter Lewitt added. “Managing symptoms of ‘Off’ periods continues to be a significant unmet need for people taking oral carbidopa/levodopa regimens. Delivering levodopa by the pulmonary route offers an important treatment option for people with Parkinson’s disease.”

ACOR shares were trading at $23.08 apiece in mid-morning activity, up +13%.

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Acorda Therapeutics

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS